IP Library › Granted Patent US 8,633,230
Granted Patent B2
US 8,633,230 · App. 11/651,672 · Granted Jan 21, 2014

Viral hepatitis treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,633,230
App. No.
11/651,672
Granted
Jan 21, 2014
Kind
B2
Abstract

The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions.

Claims (9)

1. A method of treating a patient suffering from hepatitis C comprising:

(a) pretreating the patient by administering a daily dose of 100 mg to 2000 mg of nitazoxanide to the patient for a predetermined period of time from 3 days to 28 days; and

(b) after the predetermined period of time, administering to the patient for 1-48 weeks a therapeutically effective amount of an interferon, optionally in combination with nitazoxanide and/or ribavirin.

2. The method of claim 1 , wherein the active agent is an interferon selected from interferon α-2a, interferon α-2b, and a polyethylene glycol derivative of interferon α-2a or interferon α-2b.

3. The method of claim 1 , wherein ribavirin is not administered during step (b).

4. The method of claim 3 , wherein nitazoxanide is not administered during step (b).

5. The method of claim 1 , wherein nitazoxanide is administered during step (b).

6. The method of claim 1 , wherein the administration of interferon during step (b) is for a period of 24-48 weeks.

7. The method of claim 1 , wherein the predetermined period of time of step (a) is from 7 days to 28 days.

Assignments (11)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →
SECURITY INTEREST Recorded Jul 2, 2018
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 046254/0524 →
SECURITY INTEREST Recorded Dec 22, 2017
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 044472/0001 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: ROMARK LABORATORIES, L.C.; ROMARK MANUFACTURING, LLC; LAPICOR, N.V.
Reel/Frame 035108/0474 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: ROMARK LABORATORIES, L.C.; ROMARK MANUFACTURING, LLC; LAPICOR, N.V.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 031156/0923 →
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2013
From: PAUL CAPITAL FUND MANAGEMENT, L.L.C.
To: ROMARK LABORATORIES, L.C.
Reel/Frame 031159/0636 →
CHANGE OF NAME Recorded Jul 29, 2011
From: LAMINAR DIRECT CAPITAL L.P.
To: LAMINAR DIRECT CAPITAL, L.L.C. (FORMERLY KNOWN AS LAMINAR DIRECT CAPITAL L.P.)
Reel/Frame 026676/0386 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2011
From: LAMINAR DIRECT CAPITAL, L.L.C. (FORMERLY KNOWN AS LAMINAR DIRECT CAPITAL L.P.)
To: ROMARK LABORATORIES, L.C.
Reel/Frame 026676/0576 →
SECURITY AGREEMENT Recorded Jul 29, 2011
From: ROMARK LABORATORIES, L.C.
To: PAUL CAPITAL FUND MANAGEMENT, L.L.C.
Reel/Frame 026676/0635 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 28, 2009
From: ROMARK LABORATORIES, L.C.
To: LAMINAR DIRECT CAPITAL, L.L.C., AS COLLATERAL AGENT
Reel/Frame 023282/0880 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2008
From: ROSSIGNOL, JEAN-FRANCOIS
To: ROMARK LABORATORIES, L.C.
Reel/Frame 021487/0446 →